Psoriasis: Latest News, Top Stories & Analysis

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra (JNJ-2113), a groundbreaking oral peptide designed to selectively block …

Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market

November 19, 2024November 18, 2024 - by Timothy Alexander

MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through its subsidiary, Paladin Pharma Inc. This strategic move …

Promising Breakthrough in Psoriasis Treatment: Johnson & Johnson’s JNJ-2113 Achieves Stellar Results

February 11, 2024February 11, 2024 - by Timothy Alexander

SPRING HOUSE, PA — In a remarkable breakthrough for the healthcare industry, Johnson & Johnson’s investigational targeted oral peptide, JNJ-2113, has displayed positive results in a Phase 2b study for …